We are cultivating a differentiated pipeline of small molecule medicines that utilize first-in-class or potential best-in-class mechanisms of action (MoAs) to reduce the neuronal hyperexcitability that underlies debilitating brain conditions including epilepsy. Our unique understanding of the complexities of neurologic systems allows us to turn preclinical potential into clinical meaning.

Our aim is to make a meaningful impact and address the significant unmet need in the lives of individuals with epilepsies and neurological disorders that present with brain conditions.

ProgramIndicationPreclinicalPhase 1Phase 2Phase 3Approved
+
Soticlestat
Cholesterol 24-hydroxylase inhibitorDravet syndrome
Out-licensed toTakeda logoLennox-Gastaut syndrome
+
OV888 & ROCK2 Platform*

Selective ROCK2 inhibitor

Collaboration with Graviton logo
Brainstem cavernous malformations, undisclosed rare CNS indications
+
OV329

GABA-aminotransferase inhibitor

In-licensed from Northwestern University logo
Oral formulation for chronic treatment of epilepsies

GABA-aminotransferase inhibitor

In-licensed from Northwestern University logo
IV formulation for acute treatment of seizures
+
OV350 & KCC2 Platform

KCC2 transporter activators

In-licensed from Astra Zeneca
Resistant epilepsies and other neuropathologies
DrugIndicationStage
Soticlestat
Cholesterol 24-hydroxylase inhibitorDravet syndrome Approved
Out-licensed toTakeda logoLennox-Gastaut syndrome Approved
OV888 & ROCK2 Platform*

Selective ROCK2 inhibitor

Collaboration with Graviton logo
Brainstem cavernous malformations, undisclosed rare CNS indications Phase 2
OV329

GABA-aminotransferase inhibitor

In-licensed from Northwestern University logo
Oral formulation for chronic treatment of epilepsies Phase 1

GABA-aminotransferase inhibitor

In-licensed from Northwestern University logo
IV formulation for acute treatment of seizures Preclinical
OV350 & KCC2 Platform

KCC2 transporter activators

In-licensed from Astra Zeneca
Resistant epilepsies and other neuropathologies Preclinical

*Undisclosed ROCK2 inhibitor programs

Publications and Posters ยป